ZaiLab and NovoCure surged on positive readout of Optune’s Phase III on Non-Small-Cell-Lung Cancer (NSCLC). We, however, caution that Optune faces uncertainty in commercialization.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.